HighRequires reviewPossible concern
Declining renal function (eGFR 42 mL/min/1.73m²) in a patient continuing metformin 1000 mg twice daily approaches the threshold where FDA labeling recommends dose reduction and increased monitoring for lactic acidosis risk.
Rationale
eGFR has declined from 71 to 42 mL/min/1.73m² over the past two years while metformin dosing has remained unchanged at 1000 mg twice daily. The FDA label for metformin recommends reassessing benefits and risks of continued use when eGFR falls below 45 mL/min/1.73m², and metformin is contraindicated below 30 mL/min/1.73m² due to lactic acidosis risk. No dose adjustment or renal-function-based reassessment is documented in the chart.
Recommended action
Consider reducing metformin dose, increasing renal function monitoring frequency, or evaluating alternative glycemic therapy given the current eGFR trend.
Supporting chart evidence
- eGFR (BMP): 42 mL/min/1.73m² on 2026-08-05 (prior reading 48 mL/min/1.73m² on 2026-02-11)
- Active medication: Metformin 1000 mg PO twice daily, unchanged since 2024-06-10
- Active diagnosis: Type 2 diabetes mellitus, diagnosed 2024-03-18
Clinician label